GBS News and Press, GBS Inc. From 09/01/21

Gainers: ABVC BioPharma (NASDAQ:ABVC) +32%, Bellicum Pharmaceuticals (NASDAQ:BLCM) +22%, Evaxion Biotech (NASDAQ:EVAX) +22%, GBS (NASDAQ:GBS) +22%, PetVivo (NASDAQ:PETV) +17%. Losers: Avidity Biosciences (NASDAQ:RNA) -18%, So-Young (...

GBS (NASDAQ:GBS) +51%. Anaplan PLAN +17% on Q2 earnings. Bellicum Pharmaceuticals (NASDAQ:BLCM) +16% and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch Skillz  (NYSE:SKLZ) +11%. Conn's CONN +11% on Q2 earnings. PVH PVH&...

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets. GBS currently trades at around $3, which is an attractive entry point for investors. ...

Sonoma Pharmaceuticals (NASDAQ:SNOA) +78% expanded dental care line with a new product for professional Care in the U.S. and a new product for professional and consumer care in Switzerland DLocal (NASDAQ:DLO) +20% on Q2 earnings. NLS Pharmaceutics (NASDAQ:NLSP) +14% after mazin...

Start Time: 16:30 End Time: 16:56 GBS Inc. (GBS) Q4 2021 Earnings Conference Call August 11, 2021, 16:30 PM ET Company Participants Harry Simeonidis - President and CEO Spiro Sakiris - CFO Alex Arzeno - VP, IR Conference Call Participants John Vandermosten - Zacks SCR Presentation Operator Gr...

- Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility - - Signs Strategic Partnerships with Johns Hopkins University, Wyss Institute from Harvard University, University of Newcastle and Precision Medical Architects - ...

GBS Inc. is a developer of pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications. GBS has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The compan...

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the four...

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced L.E.K. Consulting Hong Kong Pty Limited (“L.E.K. Con...

Gainers: AcelRx Pharmaceuticals ACRX +19%, GBS (GBS) +13%, Navidea Biopharmaceuticals (NAVB) +7%, Cellect Biotechnology (APOP) +6%, Adagene (ADAG) +2%.Losers: Allied Healthcare Products (AHPI) -34%, Allena Pharmaceuticals (ALNA) -31%, SCWorx (WORX)...